X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1064) 1064
Publication (93) 93
Book Review (50) 50
Book Chapter (24) 24
Dissertation (5) 5
Conference Proceeding (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
non-nucleoside reverse transcriptase inhibitors (578) 578
humans (547) 547
index medicus (394) 394
hiv (368) 368
hiv infections - drug therapy (320) 320
antiretroviral therapy (284) 284
pharmacology & pharmacy (263) 263
infectious diseases (260) 260
protease inhibitors (257) 257
rna-directed dna polymerase (227) 227
antiviral agents (226) 226
nucleoside reverse transcriptase inhibitors (226) 226
hiv-1 - drug effects (225) 225
female (221) 221
male (213) 213
reverse transcriptase inhibitors - pharmacology (204) 204
human immunodeficiency virus--hiv (197) 197
drug resistance (192) 192
adult (191) 191
efavirenz (190) 190
antiretroviral drugs (188) 188
mutation (187) 187
virology (186) 186
non-nucleoside reverse transcriptase inhibitor (174) 174
anti-hiv agents - pharmacology (166) 166
hiv-1 (163) 163
nevirapine (156) 156
anti-hiv agents - therapeutic use (155) 155
reverse transcriptase inhibitors - therapeutic use (152) 152
dna polymerases (138) 138
proteinase inhibitors (136) 136
immunodeficiency-virus type-1 (133) 133
immunology (132) 132
aids (131) 131
highly active antiretroviral therapy (131) 131
antiretroviral agents (130) 130
reverse transcriptase inhibitors - chemistry (130) 130
chemistry, medicinal (129) 129
hiv reverse transcriptase - antagonists & inhibitors (128) 128
hiv-1 - genetics (128) 128
middle aged (124) 124
hiv infections - virology (122) 122
nucleosides (122) 122
therapy (120) 120
human-immunodeficiency-virus (117) 117
infection (115) 115
drug therapy (107) 107
reverse transcriptase (107) 107
biochemistry & molecular biology (102) 102
analysis (101) 101
hiv infection (95) 95
human immunodeficiency virus (94) 94
inhibitors (93) 93
reverse-transcriptase inhibitors (93) 93
drugs (88) 88
acquired immune deficiency syndrome--aids (84) 84
nonnucleoside inhibitors (84) 84
microbiology (83) 83
viral load (83) 83
drug resistance, viral (80) 80
pharmacokinetics (80) 80
resistance (80) 80
anti-hiv agents - chemistry (79) 79
virus diseases (79) 79
structure-activity relationship (78) 78
treatment outcome (77) 77
models, molecular (75) 75
acquired immune deficiency syndrome (74) 74
anti-hiv agents (74) 74
reverse transcriptase inhibitors (73) 73
drug resistance, viral - genetics (71) 71
hiv reverse transcriptase - genetics (71) 71
ritonavir (70) 70
zidovudine (70) 70
adolescent (68) 68
hiv-1 - enzymology (68) 68
chemistry, multidisciplinary (66) 66
design (66) 66
animals (65) 65
drug-resistance (65) 65
cd4 antigen (64) 64
drug therapy, combination (64) 64
medicine & public health (64) 64
mutations (64) 64
reverse transcriptase inhibitors - chemical synthesis (64) 64
anti-hiv agents - administration & dosage (63) 63
cd4 lymphocyte count (63) 63
etravirine (61) 61
genotype (61) 61
health aspects (61) 61
hiv reverse transcriptase - metabolism (61) 61
article (60) 60
viruses (59) 59
drug design (58) 58
drug interactions (58) 58
anti-hiv agents - pharmacokinetics (57) 57
antiretroviral therapy, highly active (57) 57
patients (57) 57
protease inhibitor (57) 57
tenofovir (57) 57
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1063) 1063
French (12) 12
Spanish (10) 10
German (6) 6
Turkish (3) 3
Chinese (2) 2
Czech (1) 1
Japanese (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 229 - 237
Summary Background The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ZIDOVUDINE | COMBINATION THERAPY | ACTIVE ANTIRETROVIRAL THERAPY | EMTRICITABINE | PROTEASE-INHIBITOR | CYSTATIN-C | CREATININE | DAILY LAMIVUDINE | NEVIRAPINE | TENOFOVIR | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Nucleotides - therapeutic use | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Nucleosides - therapeutic use | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Benzoxazines - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Evaluation | Patient outcomes | Clinical trials | Dosage and administration | Drug therapy | HIV infection | Design | Antiretroviral drugs | Corporate sponsorship | Human immunodeficiency virus--HIV | Technological change | Research | Clinical medicine | Drugs | RNA-directed DNA polymerase | Exanthema | antiretroviral therapy | Lamivudine | Lipids | Nucleotides | Regression analysis | Efavirenz | CD4 antigen | nucleosides | Algorithms | Hospitals | non-nucleoside reverse transcriptase inhibitors | Abacavir | Zidovudine | Pharmaceuticals
Journal Article
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 07/2011, Volume 19, Issue 14, pp. 4227 - 4237
Journal Article
Applied Microbiology and Biotechnology, ISSN 0175-7598, 12/2018, Volume 102, Issue 23, pp. 9925 - 9936
Journal Article
Journal of the International AIDS Society, ISSN 1758-2652, 01/2013, Volume 16, Issue 1, pp. 1 - n/a
Introduction Human immunodeficiency virus (HIV) type‐1 non‐nucleoside and nucleoside reverse transcriptase inhibitors (NNRTIs) are key drugs of highly active... 
nevirapine | delavirdine | non‐nucleoside reverse transcriptase inhibitors | next‐generation non‐nucleoside reverse transcriptase inhibitors | human immunodeficiency virus | etravirine | efavirenz | rilpivirine | Next-generation non-nucleoside reverse transcriptase inhibitors | Non-nucleoside reverse transcriptase inhibitors | Nevirapine | Rilpivirine | Etravirine | Human immunodeficiency virus | Efavirenz | Delavirdine | LERSIVIRINE UK-453,061 | STEADY-STATE PHARMACOKINETICS | INFECTIOUS DISEASES | next-generation non-nucleoside reverse transcriptase inhibitors | EXPERIENCED HIV-1-INFECTED PATIENTS | POSITIONAL ADAPTABILITY | SINGLE-DOSE PHARMACOKINETICS | ANTIRETROVIRAL THERAPY | IMMUNOLOGY | TREATMENT-NAIVE | non-nucleoside reverse transcriptase inhibitors | IMMUNODEFICIENCY-VIRUS TYPE-1 | DOUBLE-BLIND | ANTIVIRAL ACTIVITY | Humans | Drug Discovery - trends | HIV Reverse Transcriptase - pharmacokinetics | HIV Reverse Transcriptase - pharmacology | HIV Infections - drug therapy | Treatment Outcome | Drug Approval | Antiretroviral Therapy, Highly Active - methods | HIV Reverse Transcriptase - adverse effects | Highly active antiretroviral therapy | Usage | Reverse transcriptase inhibitors | Research | Drug therapy | HIV infection | Health aspects | Antiretroviral drugs | Viruses | FDA approval | Mutation | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV
Journal Article
Journal Article